7 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma - Recurrence-free Survival in the
Stage III or IV Melanoma ... Population #EBM #Honc ... Nivolumab #Ipilimumab #Melanoma ... #NEJM
Melanoma of the Foot - The physical examination revealed a well-defined, fleshy, reddish plaque measuring 2
Melanoma of the ... A melanoma with ... Derm #Podiatry #Honc ... AmelanoticMelanoma #Amelanotic #Melanoma ... #Foot #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
Non–Small-Cell Lung Cancer (NSCLC ... classification of NSCLC ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM
Upper endoscopy revealed a pigmented mass in the duodenal bulb (Panel A) and two additional masses
Clinical #GI #Derm #Honc ... #Melanoma #Duodenum ... EGD #Metastatic #NEJM